ALNYLAM PHARMACEUTICALS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -28.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-12
- ALNYLAM PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was -28.10%, a 392.71% decline from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 9.60%, a 146.15% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was 3.90%, a 11.36% decline from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was 4.40%, a 4.35% decline from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | -28.10% 10-K · filed 2026-02-12 |
| 2024-12-31 | 9.60% 10-K · filed 2026-02-12 |
| 2023-12-31 | 3.90% 10-K · filed 2026-02-12 |
| 2022-12-31 | 4.40% 10-K · filed 2025-02-13 |
| 2021-12-31 | 4.60% 10-K · filed 2024-02-15 |
| 2020-12-31 | 2.20% 10-K · filed 2023-02-23 |
| 2019-12-31 | 0.00% 10-K · filed 2022-02-10 |
| 2018-12-31 | 0.80% 10-K · filed 2021-02-11 |
| 2017-12-31 | 3.30% 10-K · filed 2020-02-13 |
| 2016-12-31 | -1.40% 10-K · filed 2019-02-14 |
| 2015-12-31 | -1.10% 10-K · filed 2018-02-15 |
| 2014-12-31 | -0.20% 10-K · filed 2017-02-15 |
| 2013-12-31 | 0.80% 10-K · filed 2016-02-12 |
| 2012-12-31 | -0.70% 10-K · filed 2015-02-13 |
| 2011-12-31 | -3.30% 10-K · filed 2014-02-20 |
| 2010-12-31 | -5.00% 10-K · filed 2013-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |